Dow Silicones announces ‘significant’ investment roadmap at CPhI

Dow Silicones has announced a ‘significant’ investment roadmap at CPhI in what it says will help solve the most pressing bio-pharma processing challenges – and enable faster adoption of single use systems.

The corporation, who is at CPhI Worldwide in Madrid, says the investments will help expand Dow Silicones Corporation dedicated elastomer and extrusion manufacturing capacity, and will provide a more comprehensive set of data (BPOG, endotoxins, bioburden, particulates) for the validation of its single-use components by customers as well as will help accelerate the implementation of its innovation portfolio. In addition to a capacity expansion program, Dow Silicones will upgrade its Healthcare Industries Materials Site extrusion facility to meet ISO 7 standards.

The upgraded cleanroom is anticipated to be fully operational by the end of Q1 2019.